|Recombinant Human B7-H1 protein (Catalog#10084-H08H)|
|0.2 μm filtered solution in PBS|
|This antibody was obtained from a rabbit immunized with purified, recombinant Human B7-H1 (rh B7-H1; Catalog#10084-H08H; NP_054862.1; Met 1-Thr 239) .|
No cross-reactivity in ELISA with
Mouse B7-H1 / CD274 / PD-L1
Human B7-1 / CD80 / CD28LG1
Human B7-2 / CD86 / CD28LG2
This B7-H1/PD-L1 antibody can not block the binding of recombinant PD1 (10377-H03H) to its recombinant ligand B7-H1/PD-L1 (10084-H02H).
This antibody can be used at 1:5000-1:10000 with the appropriate secondary reagents to detect Human B7-H1.
Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Immune Checkpoint Blockade: Blocking Antibodies Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking Antibodies
Immune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins PD-L1 / B7-H1 / CD274 Immune Checkpoint Proteins
Immune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets